PMID- 16962224
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20151119
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 31
IP  - 1
DP  - 2007 Jan 30
TI  - Quetiapine in combination with citalopram in patients with unipolar psychotic 
      depression.
PG  - 242-7
AB  - This 6-week, open-label, multicenter study evaluated the efficacy and safety of 
      quetiapine in combination with citalopram in adult patients (n=25) with 
      ICD-10/DSM-IV unipolar psychotic depression. The primary endpoint was change from 
      baseline to Week 6 in the Hamilton Depression Rating Scale (HAM-D-21) score. 
      Secondary endpoints were change from baseline to Week 6 in the Brief Psychiatric 
      Rating Scale (BPRS) and the Clinical Global Impression (CGI) Scale scores. 
      Spontaneously reported adverse events (AEs), the Simpson Angus Scale (SAS), and 
      the Udvalg for Kliniske Undersogelser (UKU) side effects rating scale scores were 
      recorded. Patients' average age was 51.4 years and baseline weight was 72.6 kg. 
      Quetiapine (50-750 mg/day, mean dose+/-SD: 303+/-118 mg/day), in combination with 
      citalopram (20-60 mg/day, mean dose+/-SD: 34+/-12 mg/day), provided significant 
      improvements in depression. Mean (+/- SD) HAM-D-21 was reduced to 13.25+/-10.87 
      at Week 6 from a baseline value of 31.21+/-5.18. Significant improvement of 
      psychotic symptoms (mean+/-SD) was indicated by the decrease from baseline 
      (59.25+/-6.60) to Week 6 (35.25+/-15.60) in BPRS scores. No serious AEs occurred. 
      The mean change in weight was +2.1 kg. Mean (+/- SD) weight at visit 1 was 72.72 
      (+/-16.34) kg and mean (SD) weight at visit 4 was 74.79 (+/-18.69) kg. Quetiapine 
      in combination with citalopram appears to be effective and is well tolerated in 
      the treatment of unipolar psychotic depression. Further studies of larger, 
      double-blind, parallel-group design are warranted to confirm these findings.
FAU - Konstantinidis, A
AU  - Konstantinidis A
AD  - Department of General Psychiatry, Medical University Vienna, Austria.
FAU - Hrubos, W
AU  - Hrubos W
FAU - Nirnberger, G
AU  - Nirnberger G
FAU - Windhager, E
AU  - Windhager E
FAU - Lehofer, M
AU  - Lehofer M
FAU - Aschauer, H
AU  - Aschauer H
FAU - Kasper, S
AU  - Kasper S
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20060907
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Dibenzothiazepines)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Affective Disorders, Psychotic/*drug therapy
MH  - Aged
MH  - Antidepressive Agents/adverse effects/*therapeutic use
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Body Weight/drug effects
MH  - Citalopram/adverse effects/*therapeutic use
MH  - Dibenzothiazepines/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Endpoint Determination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Quetiapine Fumarate
EDAT- 2006/09/12 09:00
MHDA- 2007/03/16 09:00
CRDT- 2006/09/12 09:00
PHST- 2006/09/12 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2006/09/12 09:00 [entrez]
AID - S0278-5846(06)00290-9 [pii]
AID - 10.1016/j.pnpbp.2006.07.002 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):242-7. doi: 
      10.1016/j.pnpbp.2006.07.002. Epub 2006 Sep 7.